Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Inhibition of IRES-dependent translation of caspase-2 by HuR confers chemotherapeutic drug resistance in colon carcinoma cells.

Badawi A, Biyanee A, Nasrullah U, Winslow S, Schmid T, Pfeilschifter J, Eberhardt W.

Oncotarget. 2018 Apr 6;9(26):18367-18385. doi: 10.18632/oncotarget.24840. eCollection 2018 Apr 6.

2.

Human antigen R as a predictive marker for response to gemcitabine-based chemotherapy in advanced cisplatin-resistant urothelial cancer.

Miyata Y, Mitsunari K, Akihiro A, Watanabe SI, Matsuo T, Ohba K, Sakai H.

Oncol Lett. 2017 Feb;13(2):811-818. doi: 10.3892/ol.2016.5484. Epub 2016 Dec 12.

3.

Repression of caspase-3 and RNA-binding protein HuR cleavage by cyclooxygenase-2 promotes drug resistance in oral squamous cell carcinoma.

Janakiraman H, House RP, Talwar S, Courtney SM, Hazard ES, Hardiman G, Mehrotra S, Howe PH, Gangaraju V, Palanisamy V.

Oncogene. 2017 Jun 1;36(22):3137-3148. doi: 10.1038/onc.2016.451. Epub 2016 Dec 12.

4.

Predictive and prognostic significance of cytoplasmic expression of ELAV-like protein HuR in invasive breast cancer treated with neoadjuvant chemotherapy.

Wang J, Li D, Wang B, Wu Y.

Breast Cancer Res Treat. 2013 Sep;141(2):213-24. doi: 10.1007/s10549-013-2679-7. Epub 2013 Sep 14.

PMID:
24036660
5.

MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms.

Kojima K, Fujita Y, Nozawa Y, Deguchi T, Ito M.

Prostate. 2010 Oct 1;70(14):1501-12. doi: 10.1002/pros.21185.

PMID:
20687223
6.

Regulation of cyclooxgenase-2 mRNA stability by taxanes: evidence for involvement of p38, MAPKAPK-2, and HuR.

Subbaramaiah K, Marmo TP, Dixon DA, Dannenberg AJ.

J Biol Chem. 2003 Sep 26;278(39):37637-47. Epub 2003 Jun 25.

Supplemental Content

Loading ...
Support Center